Every 10-Q that Protalix BioTherapeutics, Inc. (PLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLX filings page.
Protalix BioTherapeutics reported sharply improved results for the six months ended June 30, 2026. Total revenue was $53.6 million, up from $25.8 million a year earlier, driven mainly by a $25.0 million milestone from Chiesi tied to EU approval of the every‑four‑weeks Elfabrio dosing regimen and higher Elfabrio product sales. Revenue from selling goods rose to $27.2 million, with increased sales to Chiesi and Fiocruz partly offset by lower Pfizer orders following unusually high 2025 purchases.
The company generated operating income of $25.8 million versus a prior‑year loss, and net income of $22.1 million (basic EPS $0.28) versus a $3.5 million loss. A new Israeli R&D grant reduced reported R&D expense by $2.1 million. Cash and cash equivalents were $27.4 million and, together with short‑term deposits, totaled about $40.7 million, supporting management’s view that liquidity is sufficient for at least 12 months. The company highlights ongoing geopolitical risks in Israel, potential impacts from new U.S. pharma tariffs, and uncertainty around future Israeli R&D grants, but notes that recent regional conflicts have not yet had a material adverse effect on its operations.
Protalix BioTherapeutics reported a strong turnaround for the quarter ended March 31, 2026. Total revenue rose to $33.8M from $10.1M a year earlier, driven mainly by $26.3M of license and R&D revenue that included a $25.0M milestone from Chiesi following EU approval of the every‑four‑weeks Elfabrio dosing regimen.
The company generated net income of $18.3M, versus a net loss of $3.6M in the prior‑year quarter, with basic EPS improving to $0.23. Product sales were $7.4M, down from $10.0M, reflecting lower Elelyso volumes to Pfizer and Fiocruz, partly offset by growing Elfabrio sales to Chiesi.
Operating cash flow was $22.0M, boosting cash and cash equivalents to $41.0M and total cash plus short‑term deposits to $51.1M. Total assets reached $102.3M and stockholders’ equity $67.2M. Management believes current cash resources and deposits can fund operations for at least 12 months as R&D spending increases, including the RELEASE study and early‑stage pipeline work.
Protalix BioTherapeutics (PLX) filed its Q3 2025 10‑Q, highlighting steady operations and pipeline updates. Total revenue reached $43.6 million for the nine months ended September 30, 2025, up from $35.2 million a year ago, driven by product sales to partners. Q3 revenue was $17.9 million. The company posted Q3 net income of $2.4 million, while recording a nine‑month net loss of $1.1 million.
Cash and cash equivalents were $13.6 million, with $15.7 million in short‑term deposits. Operating cash flow was $(14.0) million for the nine months, partly offset by $9.2 million from financing, including $6.8 million raised under its Sales Agreement and $2.4 million from exercises. Approximately $15.7 million in capacity remained under the Sales Agreement as of September 30, 2025.
Leases were amended, extending options through December 31, 2031; right‑of‑use assets were remeasured by $3.1 million. The company reported its cash resources are sufficient for at least 12 months. Recent updates include an effective IND for PRX‑115 Phase 2, a CHMP negative opinion on Elfabrio’s E4W dosing with re‑examination requested, and a CFO transition. Shares outstanding were about 80,421,181 as of November 1, 2025.
Protalix BioTherapeutics (PLX) reported consolidated revenue of $25.8 million for the six months ended June 30, 2025, up from $17.2 million a year earlier, driven by product sales to Pfizer, Fiocruz and Chiesi. The company narrowed its six-month net loss to $3.5 million from $6.8 million a year ago and recorded a $0.16 million net income in the three months ended June 30, 2025. Cash and cash equivalents were $17.9 million with short-term bank deposits of $15.5 million, total assets of $78.5 million and stockholders' equity of $49.9 million.
The company generated $6.8 million net proceeds from at-the-market sales under the Sales Agreement during the six-month period and stated that cash and short-term deposits are sufficient to satisfy capital needs for at least 12 months. Commercial activities include marketed products Elfabrio and Elelyso with commercialization partners Chiesi and Pfizer, ongoing clinical programs (PRX-115, PRX-119) and manufacturing responsibilities for approved products. The filing also discloses potential operational exposure to the Israel conflict and steps taken to mitigate supply risk.